医药行业周报:中国新药闪耀2025ESMO大会,推荐相关投资机会

开源证券
Yesterday

(以下内容从开源证券《医药行业周报:中国新药闪耀2025ESMO大会,推荐相关投资机会》研报附件原文摘录)2L EGFR突变NSCLC:走出TKI耐药困境,总生存期首次明确获益芦康沙妥珠单抗是全球首个在2L EGFR TKI耐药NSCLC中达成OS、PFS双获益的药物。OptiTROP-Lung04研究结果显示,芦康沙妥珠单抗对比含铂双药化疗经BIRC评估的mPFS分别为8.3m vs4.3m,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10